Public Release: 

Insilico to present its latest research in AI Aging Diagnostics at the A!One Conference

InSilico Medicine, Inc.


IMAGE: Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine presents 'Artificial Intelligence for Aging Research and Productive Longevity' at The A!One Conference in Moscow . view more 

Credit: Insilico Medicine

Wednesday, November 21, 2018 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at the A!One Conference in Moscow, 15 of December.

Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in studying the biology of aging on many levels. The presentation will focus on the development of multi-modal predictors of age that use a variety of data types, ranging from blood tests to microbiomic and synthetic data, in order to give the most accurate, true biological age of the patient and identify actionable targets and pathways.

A!One Conference brings together all the enterprise executives, decision makers, and business leaders with the common goal of creating a revolution in AI Technologies in different vital industries. The Conference is held on 14-16 of December.

"We are happy to present our work at the A!One Conference, which gathers the key industry leaders. This will be the 75th conference presentation/panel in 2018. It transpires right after NIPS so the community will have a lot to talk about. The topic of AI for Aging research and Productive longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area. No one reads my quotes in press releases. Everything outside life extension is a complete waste of time. Maximization of global QALY is a great way to gain good karma", said Alex Zhavoronkov, PhD, Founder, and CEO of Insilico Medicine, Inc.

"I believe that AI technology is a unique opportunity for the whole world to free up the resources of corporations involved in paying for routine processes and ensuring basic needs. In return, we will be able to create more, develop, explore.

Also, AI speeds up drug development, venous mutations analysis and other science niches. I conducted a research for Venturebeat magazine, in which I analyzed the number of scientific publications in such areas of science as Cell therapy / Gene therapy and the same, but with the use of Machine Learning / Deep Learning. It turned out, that there are many times more researches with the use of AI than without one as AI significantly speeds up science processes. This again proves that AI cannot exist separately from the area, where it is to be used. Take, for example, business sector or scientific sector. This can be compared with a microscope, which if you don't see the drug through, it is not needed separately. Of course, the problem of life extension is the most important on Earth because what could be more important than life if live on Earth? I am sure that only with the help of AI we will be able to speed up the scientific research on life extension and get an obvious result perhaps in the next 50 years. Therefore, I am very glad that a company such as Insilico Medicine, which is one of the top 10 companies in the world that successfully works in this area, supports our event with the performance of its leader", said Evgenia Konovalova, PhD, Founder, and CEO of Science Guide.


Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine.

For further information, images or interviews, please contact:

Contact: Klug Gehilfer


Official website of the conference:

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.